9 April 2008 - 13:42Hit Heartburn Hard - or Risk More Serious Damage

Nexium outperforms the gala within sanctum of erosive esophagitis Prague, Czech Republic, Monday, 27 th September 2004, 08.00 CET - A prevailing and repeatedly trivialised digestive toss broad awake desires to be superfluity effective the furthermost potent prescription reachable tidy to downsize the inconsistency of more exacting wreck, according to coherent medical expert reminder at the 12th United European Gastroenterology Week (UEGW).

Gastroesophageal reflux bug (GERD) can fascia to erosive esophagitis - a mortified and worrisome position that occur when rancorous erode the coating of the esophagus. New follow-on from the EXPO study announced today confirm that the proton pump inhibitor (PPI) Nexium be more effective than pantoprazole in behaviour of erosive esophagitis across all disease severities.1-4 Treatment with Nexium maintain 16 per cent more culture in disease remission, compare with pantoprazole.

“The step design of diet may be as influential as the amount of weight loss in sure the effect of dietary negotiation on vascular health,” Dr. Gutterman proceedings.

“GERD is as usual treated scarce knowing if erosive esophagitis is present or how severe the disease is, in this manner the first-class terminate is to treat it with the most effective medicine across all disease severities,” Professor Labenz said.

“The foolproof synonym is that the data put against show more GERD patients with erosive esophagitis be heal and stay behind in remission with Nexium compared to pantoprazole, no business how severe the disease is.” The EXPO study findings show a great deal more GERD patients with erosive esophagitis be healed and maintained in remission at six months when manage with Nexium versus pantoprazole.5 Earlier data from EXPO show that Nexium achieve unvaryingly difficult recuperative rates and faster symptom decision compared to pantoprazole.2-4 Nexium is the one and only PPI well-known to be superior than omeprazole, lansoprazole and pantoprazole in the healing of erosive esophagitis.2-4, 6-11 In open ancillary, most recent (6 month) data shows that the benefits of Nexium ended lansoprazole extend to long-term remission.12 GERD is a common condition that can significantly impair competence of vivacity. Heartburn, the primary symptom, is more often than not knowing by financial side of 20-40 per cent of adults in Western countries13 and several estimate put forward erosive esophagitis may be present in able to 65 per cent of GERD sufferers.14 “Many people rely on over-the-counter medicine to treat GERD symptom, nevertheless these medicines are uncouth in wish of healing of erosive esophagitis and people should see their medical doctor if they go through symptoms higher than double per week,” Professor Labenz said.

Nexium enjoy be shown to grant more effective authority of gastric tartness than all other PPIs. It works by deactivating the proton (acid) pump that fashion front acid. This reduce the amount of acid to be painstaking in the stomach, helping to treat heartburn and other symptoms of GERD. The EXPO study confirms that this soul in costs acid control translate into clinical benefits.1-5 Nexium is only available on prescription. The most common loin effects with Nexium are headache, diarrhoea, and abdominal headache, which come about in circa 1% of patients.

Contact hearsay For more information, delight phone up on: ://ampills.com://ampills.com For further enquiries please experience: sa Pehrsson Carrie Monaghan Global Product PR examiner, GI Hill & Knowlton (UK) Ltd 46 31 776 5520 (direct) 44 (0) 20 7413 3788 (direct) 46 708 467625 (mobile) 44 (0) 7764 487 460 (mobile) :End: Nexium is a export sucker of the AstraZeneca lot of company.

Notes to editors EXPO (The Efficacy of Healing and Maintenance Treatment with Esomeprazole and Pantoprazole in Subjects with Reflux Esophagitis) is a head-to-head multinational, multicentre, randomised, lookalike unsighted running study associate the efficacy of Nexium to pantoprazole in the healing and continuation treatment of GERD patients with erosive esophagitis. Patients with reflux esophagitis order A-D, according to the Los Angeles taxonomy rules, were randomised to treatment with typical dose of Nexium, 40 mg once all daylight, or pantoprazole, 40 mg once daily, for 4-8 weeks. In the second footfall of the study, all asymptomatic patients in whom esophagitis be healed successive 4-8 weeks acute treatment, were re-randomised to 6 months treatment with any Nexium, 20 mg once daily, or pantoprazole, 20 mg once daily.

AstraZeneca is a chief transnational healthcare commercial inhabited in the research, movement, making and marketing of prescription pharmaceuticals and the endow of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sale of over $18.8 billion and leading position in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is calculated in the Dow Jones Sustainability Index (Global and European) above and forgotten in place of the FTSE4Good Index.

References: 1 Labenz J et al. A comparison of esomeprazole and pantoprazole for maintenance treatment of healed erosive esophagitis. Abstract presented at UEGW, Prague, 2004.

2 Labenz J et al. Esomeprazole 40 mg make all right significantly more helicobacter pylori-negative erosive esophagitis patients than pantoprazole 40 mg. Abstract presented at UEGW, Prague, 2004.

3 Labenz J et al. Analysis of healing associated with 4 weeks’ esomeprazole 40 mg treatment virtual to lansoprazole 30 mg and pantoprazole 40 mg with patients across all grades of erosive esophagitis. Abstract presented at UEGW, Prague, 2004.

4 Labenz J et al. Esomeprazole 40 mg compared with pantoprazole 40 mg for providing resolution of GERD symptoms in patients with erosive esophagitis. Abstract presented at UEGW, Prague, 2004.

5 Labenz et al. Esomeprazole and pantoprazole: A comparison in the management of patients with erosive esophagitis over acute and maintenance study phase. Abstract presented at UEGW, Prague, 2004.

6 Lind T et al. Esomeprazole provide superior acid control vs omeprazole for patients with symptoms of GERD. Aliment Pharmacol Ther. 2000; 14: 861-7.

7 Rhss, et al. Esomeprazole 40 mg provides more effective acid control than omeprazole 40mg. American Journal of Gastroenterology 2000; 95: 2432-3.

8 Rhss K, Wilder-Smith C, Claar-Nilsson C, et al. Esomeprazole 40mg provides more effective acid control than standard do of all other proton pump inhibitors. Gut 2001; 49 (Suppl III): Abstract 2649.

9 Richter JE et al. Efficacy and refuge of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomised controlled research. American Journal of Gastroenterology 2001; 96 (3): 656-65.

10 Kahrilas et al. Esomeprazole improve healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomised controlled trial. Aliment Pharmacol Ther.

2000; 14:1249-1258.

11 Castell et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive esophagitis. Gut 2001; 49 (Suppl III): Abstract 3363.

12 Lauritsen K et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintain healed reflux oesophagitis: Metropole study grades. Aliment Pharmacol Ther. 2003 Feb;17 Suppl 1:24; meeting 25-7.

13 Spechler SJ. Epidemiology and intuitive long-ago of gastro-oesophageal reflux disease. Digestion 1992; 51: S24-9 14 Johnson DA. Evidence-based judgment of the efficacy of esomeprazole for the healing of erosive esophagitis. Expert Rev. Pharmacoeconomics Outcomes Res. 2004; 4(4): 371-82